Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  STADA Arzneimittel    SAZ   DE0007251803

STADA ARZNEIMITTEL (SAZ)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
12/12/2017 12/13/2017 12/14/2017 12/15/2017 12/18/2017 Date
80.7(c) 80.53(c) 80.47(c) 80.4(c) 80.57 Last
29 254 68 951 28 295 71 816 20 130 Volume
+0.09% -0.21% -0.07% -0.09% +0.21% Change
More quotes
Financials (€)
Sales 2017 2 291 M
EBIT 2017 320 M
Net income 2017 161 M
Debt 2017 1 160 M
Yield 2017 1,04%
Sales 2018 2 415 M
EBIT 2018 337 M
Net income 2018 196 M
Debt 2018 1 037 M
Yield 2018 1,17%
P/E ratio 2017 30,46
P/E ratio 2018 24,42
EV / Sales2017 2,69x
EV / Sales2018 2,50x
Capitalization 5 012 M
More Financials
Company
STADA Arzneimittel AG engages in the provision of healthcare and pharmaceutical products.It operates through the Generics and Branded Products segments.The Generics segment produces and distributes generic drugs.The Branded Products segment sells branded healthcare products and medicines.The... 
Sector
Pharmaceuticals
Calendar
03/29Earnings Release
More about the company
Surperformance© ratings of STADA Arzneimittel
Trading Rating : Investor Rating :
More Ratings
Latest news on STADA ARZNEIMITTEL
12/15 Germany's Merck in fresh bid to enter U.S. MS pill market
12/14 Perrigo lines up bid for Merck's consumer health unit - sources
12/05 Paul Singer's Elliott takes stake in takeover target Uniper
12/01 Nestle, Stada prepare rival bids for Germany's Merck consumer health - source..
11/15 STADA HEALTH REPORT 2017 : Young adults lack health education
11/09 STADA ARZNEIMITTEL : shows good business development in the third quarter of 201..
11/09 STADA ARZNEIMITTEL : shows good business development in the third quarter of 201..
11/09 STADA ARZNEIMITTEL : shows good business development in the third quarter of 201..
10/27 STADA ARZNEIMITTEL : Luc Slegers to hand over responsibility for STADA Europe af..
10/17 STADA ARZNEIMITTEL : Frank Staud assumes overall responsibility for the STADA br..
More news
Sector news : Generic Pharmaceuticals
08:41aDJASTRAZENECA : Says Tagrisso Supplemental NDA Accepted by FDA
05:13aDJSANOFI : Philippines Probes Dengue Vaccination Drive That Went Ahead Despite War..
02:24aDJSANOFI : Philippines Probes Vaccination Drive Amid Red Flags
12/17 TEVA PHARMACEUTICAL INDUSTRIES : Strike over Teva Pharm job cuts briefly shuts d..
12/16 PROCTER & GAMBLE : P&G appoints Peltz to board despite losing proxy battle
More sector news : Generic Pharmaceuticals
4-Traders Strategies on STADA ARZNEIMITTEL 
STADA ARZNEIMITTEL - 2014
Bearish scenario preferred
SELL
STADA ARZNEIMITTEL - 2014
Into a recovery phase
BUY
More Strategies
News from SeekingAlpha
11/09 STADA Arzneimittel's (STDAF) CEO Claudio Albrecht on Q3 2016 Results - Earnin..
11/09 Stada Arzneimittel AG reports Q3 results
11/09 Stada Arzneimittel AG 2017 Q3 - Results - Earnings Call Slides
08/21 MERGER OF EQUALS : Linde Shares More Attractive Relative To Praxair
07/05 Second-Quarter Deals Show A Sector Set On Pause
Chart STADA ARZNEIMITTEL
Duration : Period :
STADA Arzneimittel Technical Analysis Chart | SAZ | DE0007251803 | 4-Traders
Technical analysis trends STADA ARZNEIMITTEL
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 11
Average target price 66,8 €
Spread / Average Target -17%
EPS Revisions
Managers
NameTitle
Claudio Albrecht Chairman-Executive Board
Günter von Au Chairman-Supervisory Board
Mark Burgess Keatley Chief Financial Officer
Barthold Piening Chief Technical Officer
Halil Duru Member-Supervisory Board
Sector and Competitors